Tag: Bristol-Myers
Bristol-Myers To Buy Drug Developer Turning Point For $4.1B
Bristol Myers Squibb said on Friday it will acquire drug developer Turning Point Therapeutics for $4.1 billion in cash to help bolster its arsenal...
New Mexico Opens Suit Against Gilead, Bristol-Myers, Teva Over HIV Meds
Gilead Sciences, Bristol-Myers Squibb, Gilead Sciences, and Teva Pharmaceuticals were named in a lawsuit filed by New Mexico Attorney General Hector Balderas for violating...
Bristol-Myers To Buy MyoKardia For $13B
Bristol Myers Squibb said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead...
US: Bristol-Myers plans to divest psoriasis drug for merger
Bristol-Myers Squibb on Monday, June 24, offered to divest Celgene’s psoriasis treatment Otezla to allay concerns raised by the US competition regulator, and pushed...
US: Bristol-Myers to buy Celgene in a US$74B deal
Bristol-Myers Squibb announced on Thursday, January 3, it would buy Celgene for about US$74 billion, combining two of the world’s largest cancer drug businesses...
US: Bristol-Myers and Celgene in US$74B pharmaceutical merger
Bristol-Myers Squibb is buying rival Celgene in a cash and stock deal valued at about US$74 billion or US$90 billion including debt.
The tie-up, which...
US: Bristol-Myers licensing 2 compounds to raise assets
Bristol-Myers Squibb announced on Thursday that it has entered into two separate agreements with Biogen and Roche Holding to license Anti-eTau and Anti-Myostatin Compounds,...
